Fujirebio Enhances Supply Chain Operations with Kinaxis
Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced that Fujirebio Inc., a Japanese multinational biotechnology company, is using Kinaxis and its AI-powered supply chain orchestration platform Maestro™ to enhance and optimize its supply chain operations.
Fujirebio Inc., a consolidated subsidiary of Fujirebio Holdings Inc., is a global leader in the development, manufacturing and sales of clinical diagnostic reagents and testing equipment. Fujirebio is currently focused on strengthening and expanding its Contract Development and Manufacturing Organization (CDMO) by leveraging high-quality raw materials in the immunology field and advanced reagent development technologies.
To accelerate the company’s growth, Fujirebio needed to strategically link and synchronize its entire supply chain process, which spans raw material production to final product shipment and encompasses a multi-layered and complex set of operations.
“The adoption of Kinaxis is central to building a more flexible and efficient supply chain model,” said Kazuya Saito, division head of SCM division, corporate SCM division at Fujirebio Inc. “This will enable faster strategic decision-making and accelerate our efforts toward transforming our business structure. At the same time, we aim to provide new value to the healthcare industry.”
By implementing the Maestro platform, Fujirebio is working to orchestrate demand, production and procurement planning across its supply chain, enabling fast planning simulations. This will also facilitate the establishment of an S&OP (Sales and Operations Planning) process that accelerates strategic decision-making based on financial data.
“In the healthcare industry, there is a need for advanced planning management that considers manufacturing constraints and manages inventory in both quantity and financial terms. We are pleased to support Fujirebio as they advance strategic decision-making through the use of simulations,” said Phillip Teschemacher, president of APAC at Kinaxis.
To learn more about Kinaxis and its supply chain orchestration solutions, please visit Kinaxis.com.
About Fujirebio
Fujirebio, a member of H.U. Group Holdings Inc., is a global R&D-driven company constantly developing new in vitro diagnostics testing technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care. Our global teams located in Japan, Asia, Europe, and the US focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and critical materials to supply, develop, or manufacture diagnostic solutions on a wide variety of platforms. For more information about Fujirebio, please visit www.fujirebio.com.
About Kinaxis
Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
Source: Kinaxis Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319567981/en/
Contacts
Media Relations
Matt Tatham | Kinaxis
mtatham@kinaxis.com
+1 917.446.7227
Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
+1 613-907-7613
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two Young Chefs Have Passed the Japanese Cuisine Certification Exam (Organized by JCDC) and Have Newly Acquired Gold Certification!21.3.2025 15:00:00 CET | Press Release
The Japanese Cuisine and Dietary Culture Development Committee (JCDC) (Location: Minato-ku, Tokyo; Representative: Yoshihiro Murata; Website: https://en.jcdc.tokyo/), which supports and promotes the spread of Japanese food overseas, held a certification exam for foreign chefs in Kyoto. This certification exam is based on the “Guidelines for Certification of Cooking Skills for Japanese Cuisine in Foreign Countries” (enacted on April 1, 2016 / revised on April 1, 2024) established by the Ministry of Agriculture, Forestry and Fisheries (MAFF) of Japan. In this examination, two people from Vietnam, Le Minh Tien and Pham Duc Duy, successfully obtained Gold certification. In addition, the two foreign chefs who came to Japan to participate in the Kyoto final of the “Road to Japanese Culinary Arts Award 2024-2025” hosted by the Japanese Culinary Academy were also certified as Silver. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2025
DEWA’s General Assembly Approves Dividend Payment of AED 3.1 Billion to Shareholders for H2 of 202421.3.2025 14:34:00 CET | Press Release
Dubai Electricity and Water Authority PJSC (ISIN: AED001801011) (Symbol: DEWA), the Emirate of Dubai’s exclusive electricity and water services provider, which is listed on the Dubai Financial Market (DFM), reported that its shareholders have, in the general assembly held on 21 March 2025, approved the payment of total dividend of AED 3.1 billion for H2 of 2024, with a record date of 31 March 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250321365368/en/ During DEWA’s General Assembly (Photo: AETOSWire) The meeting, chaired by HE Matar Humaid Al Tayer, Chairman of the Board of Directors of DEWA, was attended by HE Saeed Mohammed Al Tayer, MD & CEO of DEWA, and Members of the Board of Directors of DEWA as well as 92.2% of the shareholders. During the meeting, a Board of Directors was elected for the next three years. For shareholders who are invested in DEWA’s shares prior to the dividend record date of 31 March 2025 (
Ecolab Delivers on Commitments to Save Water in Historic AI Era21.3.2025 12:00:00 CET | Press Release
Water is the world’s most essential resource, and it’s only grown more critical in the age of AI. During this transformative digital revolution, Ecolab, a global sustainability leader that maximizes growth and performance through water solutions and infection prevention services, has continued to meet its goals and work with customers to deliver profitability while advancing optimized water use. By 2030, it is estimated that AI-related growth will demand additional power equivalent to the annual needs of India1 and as much water to meet the annual drinking water needs of the United States2. As the world navigates the growth of AI and high-tech data centers, there is a unique opportunity to leverage AI to help drive efficiency and innovation in circular water management to improve operational processes and conserve natural resources. Ecolab’s mission to help protect water while driving business growth is more important than ever. “The rapid acceleration of AI technology is increasing de
Galderma Publishes its 2024 Annual Report and the Invitation to Its First Annual General Meeting21.3.2025 07:00:00 CET | Press Release
Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published its 2024 Annual Report along with the invitation to its first Annual General Meeting which will be held on April 23, 2025. Galderma’s 2024 Annual Report, the 2024 Finance Report and the invitation to the Annual General Meeting are available on Galderma’s Investor Relations website at https://investors.galderma.com/. About Galderma Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals
Almirall's 16 th Skin Academy Brings Together Leading Experts to Advance Skin Science and Treatment Options in Medical Dermatology21.3.2025 07:00:00 CET | Press Release
Almirall, a global pharmaceutical company dedicated to medical dermatology hosts the 16th edition of Skin Academy, a premier conference for healthcare professionals in the field of dermatology. This year's event features a comprehensive program aimed at sharing state-of-the-art scientific knowledge on skin diseases, their treatment, and clinical best practice. The Skin Academy is a unique opportunity for collaboration, bringing together a broad range of leading experts and clinicians from across the globe to create a network of peers that discuss and learn together to advance the treatment of skin diseases. The event will foster collaboration and co-creation of innovative approaches and solutions to better respond to the unmet needs of the millions of people living with dermatological conditions. Prof. Dr. Ulrich Mrowietz, from the Psoriasis Center at the University Medical Center Schleswig-Holstein, Campus Kielin Germany said: "deep collaboration across experts is essential for advanc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom